Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001903943 | SCV002122063 | uncertain significance | Neuroblastoma, susceptibility to, 3 | 2021-10-13 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. This variant has not been reported in the literature in individuals affected with ALK-related conditions. This variant is present in population databases (rs78086548, ExAC 0.02%). This sequence change replaces glycine with arginine at codon 924 of the ALK protein (p.Gly924Arg). The glycine residue is highly conserved and there is a moderate physicochemical difference between glycine and arginine. |
Gene |
RCV003442922 | SCV004167888 | uncertain significance | not provided | 2023-04-12 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |